Nyheder

Lundbeckfonden Ventures nyheder

CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, and Everest Medicines announced today that they have entered into a collaboration to develop, manufacture and commercialize SPR206 in Greater China, South Korea and certain...
CAMBRIDGE, Mass. Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it has received written confirmation from the U.S. Food and Drug Administration (FDA) regarding agreement on the design of its Phase 3 registration trials designed to evaluate light-activated AU-011 for the treatment of patients with choroidal...
Lund, Sweden, 8:00 CET, January 4 2019 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, announces changes in its leadership team that will take place March 1, 2019. Annelie Aava Vikner starts in a new position as the company´s Executive Vice President Global Marketing & Communications. Annelie Aava Vikner has...
January 3, 2019 Tiburio raises $31M in a Series A round to advance two clinical stage compounds TBR-760, for the treatment of nonfunctioning pituitary adenoma (NFPA), and TBR-065 for rare endocrine diseases Tiburio appoints Abraham N. Ceesay as Chief Executive Officer Cambridge, MA, January 3, 2019 – Cydan today announced the launch of Tiburio Therapeutics Inc....
Det nystartede amerikanske selskab Tiburio, der er i gang med at udvikle et middel mod sjældne tumorer tæt ved hypofysen, henter en samlet investering på godt 200 mio. kr. – bl.a. fra Lundbeckfonden Ventures. Lundbeckfonden Ventures har – sammen med en række andre investorer – investeret i alt 200 mio. kr. i det nystartede Tiburio....
Lund, Sweden, 18:00 CET 28 December 2018 – During December, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 28 December 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 51,795,917. For more information contact: BONESUPPORT AB Emil...
Mette Kirstine Agger, Managing Partner i Lundbeckfonden Ventures, blev interviewet af Labiotech under BIO-europe konferencen, november 2018. Se hele interviewet her:      
November 27, 2018 09:00 AM Eastern Standard Time EDINBURGH, Scotland–(BUSINESS WIRE)–DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra Colposcope used in cervical cancer screening, announced today the appointment of Darin Hammers as Chief Executive Officer and a member of the board of directors. In addition, Michael Gioffredi was appointed as Chief Commercial Officer....
Cambridge, UK and Indianapolis, US – 21 November 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that data and analyses from its positive Phase 3 clinical trial of BARHEMSYS(TM) (intravenous amisulpride) as rescue treatment of established post-operative nausea & vomiting (PONV) have been published (Habib et al1) in the online edition...
1 2 3 48

Lundbeckfonden Ventures

Nyheder

Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial
7. januar 2019
Aura Biosciences Announces Successful Outcome of End of Phase 2 Meeting with FDA for AU-011 for the Treatment of Patients with Choroidal Melanoma
4. januar 2019
BONESUPPORT appoints Annelie Aava Vikner as Executive Vice President Global Marketing & Communications
4. januar 2019